Successful Oral Corticosteroid with Doxycycline as Adjuvant Therapy in a Case of Refractory Bullous Pemphigoid

Authors

  • Dinda Rozita Maharani Universitas Airlangga - Dr. Soetomo General Academic Hospital Surabaya
  • Septiana Widyantari Universitas Airlangga/ Dr. Soetomo General Academic Hospital of Surabaya, Indonesia.
  • Menul Ayu Umborowati Department of Dermatology and Venereology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
  • Sylvia Anggraeni Department of Dermatology and Venereology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
  • Damayanti Damayanti Universitas Airlangga/ Dr. Soetomo General Academic Hospital of Surabaya, Indonesia.
  • Cita Rosita Sigit Prakoeswa Department of Dermatology and Venereology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

Keywords:

Bullous pemphigoid; therapy; corticosteroids; doxycycline

Abstract

Bullous pemphigoid (PB) is a bullous autoimmune disease that often occurs in elderly people. It can be triggered by age, drug use, trauma, ultraviolet exposure, radiation, genetic roles and stress. Treatment of PB with topical and oral corticosteroid drugs remains the main option.1 However, recent control trial studies have shown the efficacy and safety of using doxycycline to reduce accumulated treatment dose and mortality. A 68-year-old male presented with widespread, itchy bullae that ruptured, releasing clear fluid and forming dark crusts. Physical examination revealed multiple tense bullae and erosions on the neck, trunk, and upper extremities. He was treated with oral and topical corticosteroids, wound care, topical moisturizers, and anti-inflammatory antibiotics. Clinical improvement was noted within 7 days, with continued follow-up over 2–3 months. Combined with oral and topical corticosteroids, doxycycline offers potential as a steroid-sparing agent toattenuate inflammation and prevent recurrence of PB.

Author Biographies

Septiana Widyantari, Universitas Airlangga/ Dr. Soetomo General Academic Hospital of Surabaya, Indonesia.

Department of Dermatology and Venereology, Faculty of Medicine Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, Indonesia Jalan Prof. Dr. Moestopo No. 6-8 Surabaya, East Java, 60286, Indonesia

Damayanti Damayanti, Universitas Airlangga/ Dr. Soetomo General Academic Hospital of Surabaya, Indonesia.

Department of Dermatology and Venereology, Faculty of Medicine Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, Indonesia Jalan Prof. Dr. Moestopo No. 6-8 Surabaya, East Java, 60286, Indonesia

References

Deotto ML, Spiller A, Sernicola A, Alaibac M. Bull-ous pemphigoid: An immune disorder related to aging. Exp Ther Med. 2022;23(1):50. Doi: 10.3892/etm.2021.10972.

Miyamoto D, Santi CG, Aoki V, Maruta CW. Bul-lous pemphigoid. A Bras Dermatol. 2019;94(2): 133-146. Doi 10.1590/abd1806-4841.20199007

Culton DA, Liu Zhi, Diaz LA. Bullous pemphigoid. In: Kang S, Amagai M, Bruck-ner AL, Enk AH, Margolis DJ, McMichael AJ, et al, editors. Fitzpat-rick's Dermatology in General Medicine (9th ed). New York: Mc Graw Hill Inc; 2019.p.944-52.

Bernard P, Antonicelli F. Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treat-ment. Am J Clin Dermatol. 2017;18(4):513-528. Doi: 10.1007/s40257-017-0264-2.

Rania M, Petersen LV, Benros ME, Liu Z, Diaz L, Bulik CM. Psychiatric comorbidity in individuals with bullous pemphigoid and all bullous disorders in the Danish national registers. BMC psychiatry. 2020;20(1): 411. Doi: 10.1186/s12888-020-02810-x.

Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, et al . Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomized controlled trial. Lancet. 2017;389 (10079):1630-1638.

Doi: 10.1016/S0140-6736(17)30560-3.

Kimura K, Kawai K. Doxycycline as an initial treatment of bullous pemphigoid in Japanese pa-tients. Journal of Cutaneous Immunology and Al-lergy. 2020;3(4):80-5.

Singh S, Kirtschig G, Anchan VN, Chi C-C, Taghi-pour K, Boyle RJ, et al. Interventions for bullous pemphigoid Cochrane Database Syst Rev. 2023 ;8(8):CD002292.

Doi: 10.1002/14651858.CD002292.pub4.

Trisnowati DM, Budi HP, Gaspersz S, Durry M. Bullous Pemphigoid Treated with Corticosteroid: A Case Report. e-CliniC. 2022;10(2):400-5.

Mohammadi FK, Zoha S, Baleeqhuddin M, Ali SM, Faizan AM. A Case Report on Idiopathic Severe Bullous Pemphigoid. J. Drug Delivery Ther. 2020;10(4-s):223-5. Doi: 10.22270/jddt.v10i4-s.4311

Downloads

Published

2025-09-30

How to Cite

1.
Maharani DR, Widyantari S, Menul Ayu Umborowati, Sylvia Anggraeni, Damayanti D, Cita Rosita Sigit Prakoeswa. Successful Oral Corticosteroid with Doxycycline as Adjuvant Therapy in a Case of Refractory Bullous Pemphigoid. J Pak Assoc Dermatol [Internet]. 2025Sep.30 [cited 2025Dec.31];35(3):259-63. Available from: http://jpad.com.pk/index.php/jpad/article/view/2878

Issue

Section

Case Reports

Most read articles by the same author(s)